『药品』专家论坛｜邹正升：药物性肝损伤慢性化的研究近况( 四 ) |保健品|西班牙|日本|

中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南［J］．临床肝胆病杂志，2015 ，31(11): 1752-1769．
［8］AITHAL PG, DAY CP. The natural history of histologically proved drug induced liver disease［J］. Gut, 1999, 44(5): 731-735.
［9］BJ?RNSSON E, KALAITZAKIS E, AV KLINTEBERG V, et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury［J］. Aliment Pharmacol Ther, 2007, 26(1): 79-85.
［10］SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China［J］. Gastroenterology, 2019, 156(8): 2230-2241. e11.
［11］FONTANA RJ, HAYASHI PH, BARNHART H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury［J］. Am J Gastroenterol, 2015, 110(10): 1450-1459.
［12］CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study［J］. Gastroenterology, 2015, 148(7): 1340-1352. e7.
［13］BJ?RNSSON E, DAVIDSDOTTIR L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice［J］. J Hepatol, 2009, 50(3): 511-517.
［14］FONTANA RJ, SEEFF LB, ANDRADE RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop［J］. Hepatology, 2010, 52(2): 730-742.
［15］KLEINER DE, CHALASANI NP, LEE WM, et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations［J］. Hepatology, 2014, 59(2): 661-670.
［16］REUBEN A, KOCH DG, LEE WM, et al. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study［J］. Hepatology, 2010, 52(6): 2065-2076.
［17］ROBLES-DIAZ M, LUCENA MI, KAPLOWITZ N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury［J］. Gastroenterology, 2014, 147(1): 109-118. e5.
［18］LUCENA MI, KAPLOWITZ N, HALLAL H, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis［J］. J Hepatol, 2011, 55(4): 820-827.
［19］AMACHER DE, CHALASANI N. Drug-induced hepatic steatosis［J］. Semin Liver Dis, 2014, 34(2): 205-214.
［20］DANIEL F, CADRANEL JF, SEKSIK P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients［J］. Gastroenterol Clin Biol, 2005, 29(5): 600-603.
［21］CROCETTI D, PALMIERI A, PEDULLA G, et al. Peliosis hepatis: Personal experience and literature review［J］. World J Gastroenterol, 2015, 21(46): 13188-13194.
［22］SEBODE M, SCHULZ L, LOHSE AW. “Autoimmune(-Like)” drug and herb induced liver injury: New insights into molecular pathogenesis［J］. Int J Mol Sci, 2017, 18(9). pii: E1954.
［23］BONKOVSKY HL, KLEINER DE, GU J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements［J］. Hepatology, 2017, 65(4): 1267-1277.